ClinicalTrials.gg
RecruitingNCT05509725Updated Feb 20, 2024

Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)

A Phase 4 interventional study of Probiotic formulation and Placebo in IBS - Irritable Bowel Syndrome, sponsored by Lallemand Health Solutions. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Lallemand Health Solutions · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Irritable Bowel Syndrome with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Irritable Bowel Syndrome · Turkey.

Planned enrollment
2nd of 18
162 · median 60
Started
2022
with 2 others
Phase 4
Only one
of the 21
Registered
5th of 21
by date

Among the 21 studies in Irritable Bowel Syndrome with a site in Turkey, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 4, and was the 5th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

5 of the 21 studies in Irritable Bowel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Irritable Bowel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in adults with IBS-D.

Read the detailed description

To monitor safety and to evaluate the efficacy of a probiotic formulation on severity of gastrointestinal symptoms (abdominal pain, abnormal defecation), anxiety, depression and quality of life in adult participants with IBS-D.

03

Conditions studied

  • IBS - Irritable Bowel Syndrome

Keywords

  • IBS-D
  • Probiotics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Experiencing symptoms of IBS-D
  • Having a diagnosis of IBS-D based on Rome IV criteria
  • Participants with symptom onset at least 6 months before diagnosis
  • Having a normal colonoscopy result in their medical file

Exclusion criteria

Exclusion Criteria:

  • A history of inflammatory or immune-mediated gastrointestinal diseases
  • Diagnosed with a co-existing organic gastrointestinal disease which can affect the study
  • Currently undergoing a treatment for other severe conditions such as coronary disease, neurological disorder, kidney or liver disease,
  • Currently diagnosed with an eating disorder,
  • Having undergone any abdominal surgery including cholecystectomy, with the exception of hernia repair or appendectomy
  • Currently diagnosed with any mood- or anxiety-related disorder, major psychiatric illness, or participants with a history of suicidal ideation, or current suicidal ideation,
  • Regular use of anti-diarrhea medications and laxatives however occasional use is permitted (≤ than once a month); if current use is > once per month a one month wash out is needed,
  • Unwilling to avoid the use of antidiarrheal or laxative medication on an "as-needed basis" during the full length of the study,
  • Pregnant, breast-feeding or planning on becoming pregnant.
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants in this group will be randomized to receive probiotic formulation for the following 8 weeks.

    Drug: Probiotic formulation

  • Placebo comparator
    Control

    Participants in this group will be randomized to receive placebo for the following 8 weeks.

    Drug: Placebo

Interventions

  • DrugProbiotic formulation

    Participants will be asked to take 2 doses daily

  • DrugPlacebo

    Participants will be asked to take 2 doses daily

06

What researchers measure

Primary outcomes

  1. Change in Abdominal Pain

    Change in abdominal pain intensity using Visual Analog Scale (VAS) from 0 (no symptom) to 10 (worst possible)

    Time frame: 8 weeks

  2. Change in Defecation consistency

    Change in abnormal defecation consistency using the Bristol Stool Scale (BSS) from Type 1 (severe constipation) to Type 7 (severe diarrhea)

    Time frame: 8 weeks

Secondary outcomes

  1. Change Abdominal pain intensity

    Change in abdominal pain intensity using Visual Analog Scale (VAS) from 0 (no symptom) to 10 (worst possible)

    Time frame: up to 10 weeks

  2. Abnormal defecation consistency

    Change in abnormal defecation consistency using the Bristol Stool Scale (BSS) from Type 1 (severe constipation) to Type 7 (severe diarrhea)

    Time frame: up to 10 weeks

  3. Stool frequency

    Measured as the average number of stools per week

    Time frame: up to 10 weeks

  4. Abdominal discomfort

    Using questionnaire in participants diary

    Time frame: up to 10 weeks

  5. Perceived Stress

    Using the Perceived Stress Scale (PSS) grading from 0 (low stress) to 40 (high perceived stress)

    Time frame: 8 weeks

  6. Change in Irritable Bowel Syndrome Symptom Severity Scores

    Using the The irritable bowel severity scoring system (IBS-SSS)

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — After publications of the results, de-identified data will be shared with qualified researchers and scientists upon reasonable request to the sponsor including a detailed proposal of the intended use of the data, as per the Lallemand Health Solutions Inc. Policy on Clinical Trial Transparency and Data Sharing (available upon request).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Nov 2024, 27 months after the start.

Of 24 phase 4 interventional studies under Irritable Bowel Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 29. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Aug 22, 2022
StartActual
Aug 11, 2022
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05509725
Lead sponsor
Lallemand Health Solutions
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Aug 11, 2022
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
Feb 20, 2024

Study contacts

Burcu Sume
Contact
burcus@croturk.com
+90 312 479 88 75
Serhat Bor, Prof. Dr.
principal investigator · Ege University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion